The Role of FDG-PET and Whole-Body MRI in High Grade Bone Sarcomas With Particular Focus on Osteosarcoma

Farina, Arianna; Gasperini, Chiara; Gómez, Maria Pilar Aparisi; Bazzocchi, Alberto; Fanti, Stefano; Nanni, Cristina

doi:10.1053/j.semnuclmed.2021.10.001

Cited by 10 publications

(15 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several recent reports have suggested SUV analytical values for predicting patient outcomes in lung cancer [10][11][12][13][14][15][16][17]. A similar quantitative analysis of FDG uptake has also been applied in prognostic studies of other cancers [18][19][20][21].…”

Section: Risk Analysismentioning

confidence: 99%

“…Numerous studies have considered biochemical changes assessed using FDG-PET as a sensitive marker compared with morphological changes estimated using computed tomography (CT) or magnetic resonance imaging (MRI). In addition, patients with a complete metabolic response after therapy may show better disease-free survival and overall survival than those with any other responses [9][10][11][12][13][14][15][16][17][18][19][20][21]. Precise assessment of treatment response is required, mainly because of the rapid progress in new treatments for various cancers.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Four-dimensional quantitative analysis using FDG-PET in clinical oncology

et al. 2023

View full text Add to dashboard Cite

Positron emission tomography (PET) with F-18 fluorodeoxyglucose (FDG) has been commonly used in many oncological areas. High-resolution PET permits a three-dimensional analysis of FDG distributions on various lesions in vivo, which can be applied for tissue characterization, risk analysis, and treatment monitoring after chemoradiotherapy and immunotherapy. Metabolic changes can be assessed using the tumor absolute FDG uptake as standardized uptake value (SUV) and metabolic tumor volume (MTV). In addition, tumor heterogeneity assessment can potentially estimate tumor aggressiveness and resistance to chemoradiotherapy. Attempts have been made to quantify intratumoral heterogeneity using radiomics. Recent reports have indicated the clinical feasibility of a dynamic FDG PET-computed tomography (CT) in pilot cohort studies of oncological cases. Dynamic imaging permits the assessment of temporal changes in FDG uptake after administration, which is particularly useful for differentiating pathological from physiological uptakes with high diagnostic accuracy. In addition, several new parameters have been introduced for the in vivo quantitative analysis of FDG metabolic processes. Thus, a four-dimensional FDG PET-CT is available for precise tissue characterization of various lesions. This review introduces various new techniques for the quantitative analysis of FDG distribution and glucose metabolism using a four-dimensional FDG analysis with PET-CT. This elegant study reveals the important role of tissue characterization and treatment strategies in oncology.

show abstract

Section: Risk Analysismentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Four-dimensional quantitative analysis using FDG-PET in clinical oncology

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Extrapulmonary metastases primarily involve the bone and bone marrow and portend a worse prognosis than localized disease or pulmonary metastases alone 9,41,42,50,51 . 18F‐FDG PET/CT has been shown to be more accurate than whole‐body Tc99m‐methylene diphosphonate (Tc99m‐MDP) bone scintigraphy for detection of extrapulmonary metastases in both OS and EWS, particularly within the spine and pelvis 52–72 . Use of 18F‐FDG PET/CT for staging allows potential omission of bone marrow biopsy in EWS patients 73–76 .…”

Section: Imaging At Diagnosismentioning

confidence: 99%

Imaging of pediatric bone tumors: A COG Diagnostic Imaging Committee/SPR Oncology Committee White Paper

Cederberg

Iyer

Chaturvedi

et al. 2022

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…SUV-max, the most used parameter for measuring the metabolic activity of tumors, 33 has been reported as a biomarker for predicting survival in OS, the likelihood of metastasis, and response to chemotherapy. [34][35][36] Here, we found that MAGE-A4 expression was correlated with the SUV-max value, suggesting that MAGE-A4 may be considered a biomarker for metastasis, and response to chemotherapy in OS.…”

Section: Articlementioning

confidence: 99%

Clinicopathological assessment of cancer/testis antigens NY‑ESO‑1 and MAGE‑A4 in osteosarcoma

et al. 2022

View full text Add to dashboard Cite

The cancer/testis antigens (CTAs), New York esophageal squamous cell carcinoma-1 (NY-ESO-1) and melanoma antigen gene (MAGE)-A4 are normally restricted to male germ cells but are aberrantly expressed in several cancers. Considering the limited information regarding their significance in osteosarcoma (OS), the purpose of this study was to determine the clinical significance of NY-ESO-1 and MAGE-A4 expression in OS. Nine patients with OS treated at Kindai University Hospital were included in the study. The median age was 27 years, and median follow-up period was 40 months. The specimens obtained at the time of biopsy were used to perform immunostaining for NY-ESO, MAGE-A4, p53, and Ki-67. The positive cell rates and positive case rates of NY-ESO, MAGE-A4, p53, and Ki-67 were calculated. The correlation between the positive cell rate of immunohistochemical markers was also calculated. The correlation between the positive cell rate of NY-ESO-1 or MAGE-A4 and tumor size or maximum standardized uptake (SUV-max) was also determined. The positive cell rates of NY-ESO-1 or MAGE-A4 in continuous disease-free (CDF) cases were also compared with those in alive with disease (AWD) or dead of disease (DOD) cases. The average positive cell rates of NY-ESO, MAGEA4, p53, and Ki-67 were 71.7%, 85.1%, 16.2%, and 14.7%, and their positive case rates were 33.3%, 100%, 44.4%, and 100%, respectively. The positivity rates of NY-ESO-1 and p53 were strongly correlated, whereas those of NY-ESO-1 and Ki-67 were moderately correlated. The MAGE-A4 and p53 positivity rates and the MAGE-A4 and Ki-67 positive cell rates were both strongly correlated. The NY-ESO-1 and MAGE-A4 positivity rates were moderately correlated. The positive correlation between the NY-ESO-1 positive cell rate and tumor size was medium, and that between the MAGE-A4 positivity rate and SUV-max was very strong. There was no significant difference in the positive cell rates of NY-ESO-1 or MAGE-A4 between CDF cases and AWD or DOD cases. Overall, our results suggest that NY-ESO-1 and MAGE-A4 may be involved in the aggressiveness of OS.

show abstract

The Role of FDG-PET and Whole-Body MRI in High Grade Bone Sarcomas With Particular Focus on Osteosarcoma

Cited by 10 publications

References 37 publications

Four-dimensional quantitative analysis using FDG-PET in clinical oncology

Four-dimensional quantitative analysis using FDG-PET in clinical oncology

Imaging of pediatric bone tumors: A COG Diagnostic Imaging Committee/SPR Oncology Committee White Paper

Clinicopathological assessment of cancer/testis antigens NY‑ESO‑1 and MAGE‑A4 in osteosarcoma

Contact Info

Product

Resources

About